Latest News
General Proximity De-Stealths with $16M to Pioneer Next-Gen Induced Proximity Medicines for 'Undruggable' Targets
General Proximity announced its emergence from stealth, unveiling its proprietary OmniTAC platform designed to pioneer the next generation of induced proximity medicines.
January 3, 2025
Axios Exclusive: General Proximity Gets $8M for Drug Discovery
Drug discovery platform General Proximity raised an $8 million seed, CEO Armand Cognetta tells Axios exclusively.
December 18, 2024
General Proximity Has Been Selected as One of the 24 ARPA-H Sprint for Women’s Health Awardees to Receive $3M to Develop Our Main Program
We are thrilled to announce that General Proximity has been selected as one of the 24 awardees of the highly competitive Advanced Research Projects Agency for Health (ARPA-H) Sprint for Women’s Health.
October 23, 2024
Dr. Andy Crew, Former CTO of Arvinas, Joins Our Scientific Advisory Board
We are excited to announce that Dr. Andy Crew has joined General Proximity's Scientific Advisory Board. Dr. Crew is a seasoned expert in drug discovery with a strong focus on induced proximity. Previously, he served as Chief Technology Officer at Siduma Therapeutics and Arvinas.
September 1, 2024
Dr. Scott Forrest Joins General Proximity's Strategic Advisory Board
We are pleased to announce that Dr. Scott Forrest has joined General Proximity's Strategic Board. Dr. Forrest is currently the Chief Business Officer at Shoreline Therapeutics and brings a wealth of experience in corporate development and financial strategy.
August 15, 2024
General Proximity Welcomes Dr. Steve W. Djuric as New Advisor
We are thrilled to announce that Dr. Steve W. Djuric has joined General Proximity as an Advisor. Dr. Djuric brings a wealth of experience from his previous role as Vice President of Discovery Chemistry and Technology at AbbVie, where he led their global Medicinal Chemistry Leadership Team.
August 15, 2024
Expansion of General Proximity's Clinical Advisor Board: Building on Our DMPK Expertise with Dr. Gondi Kumar
We are excited to announce that Gondi Kumar has joined General Proximity as an Advisor. Gondi brings over 30 years of extensive experience in pharmaceutical research and development, most recently serving as Senior Vice President of Nonclinical R&D at Bristol Myers Squibb (BMS).
July 25, 2024
NIH NCI SBIR Phase I Award
We are proud to announce that General Proximity has been awarded a NIH NCI SBIR Phase I grant. This $400k grant will drive our efforts to develop groundbreaking treatments targeting Triple Negative Breast Cancer (TNBC), one of the most challenging and aggressive forms of breast cancer.
February 1, 2024
General Proximity Has Been Selected as One of the 24 ARPA-H Sprint for Women’s Health Awardees to Receive $3M to Develop Our Main Program
We are thrilled to announce that General Proximity has been selected as one of the 24 awardees of the highly competitive Advanced Research Projects Agency for Health (ARPA-H) Sprint for Women’s Health.
October 23, 2024
Dr. Andy Crew, Former CTO of Arvinas, Joins Our Scientific Advisory Board
We are excited to announce that Dr. Andy Crew has joined General Proximity's Scientific Advisory Board. Dr. Crew is a seasoned expert in drug discovery with a strong focus on induced proximity. Previously, he served as Chief Technology Officer at Siduma Therapeutics and Arvinas.
September 1, 2024
Dr. Scott Forrest Joins General Proximity's Strategic Advisory Board
We are pleased to announce that Dr. Scott Forrest has joined General Proximity's Strategic Board. Dr. Forrest is currently the Chief Business Officer at Shoreline Therapeutics and brings a wealth of experience in corporate development and financial strategy.
August 15, 2024
General Proximity Welcomes Dr. Steve W. Djuric as New Advisor
We are thrilled to announce that Dr. Steve W. Djuric has joined General Proximity as an Advisor. Dr. Djuric brings a wealth of experience from his previous role as Vice President of Discovery Chemistry and Technology at AbbVie, where he led their global Medicinal Chemistry Leadership Team.
August 15, 2024
Expansion of General Proximity's Clinical Advisor Board: Building on Our DMPK Expertise with Dr. Gondi Kumar
We are excited to announce that Gondi Kumar has joined General Proximity as an Advisor. Gondi brings over 30 years of extensive experience in pharmaceutical research and development, most recently serving as Senior Vice President of Nonclinical R&D at Bristol Myers Squibb (BMS).
July 25, 2024
NIH NCI SBIR Phase I Award
We are proud to announce that General Proximity has been awarded a NIH NCI SBIR Phase I grant. This $400k grant will drive our efforts to develop groundbreaking treatments targeting Triple Negative Breast Cancer (TNBC), one of the most challenging and aggressive forms of breast cancer.
February 1, 2024
General Proximity De-Stealths with $16M to Pioneer Next-Gen Induced Proximity Medicines for 'Undruggable' Targets
General Proximity announced its emergence from stealth, unveiling its proprietary OmniTAC platform designed to pioneer the next generation of induced proximity medicines.
January 3, 2025
Axios Exclusive: General Proximity Gets $8M for Drug Discovery
Drug discovery platform General Proximity raised an $8 million seed, CEO Armand Cognetta tells Axios exclusively.
December 18, 2024